Summary
Over the last five years many large pharma companies have expanded rapidly in emerging markets. Leading among the pack are Glaxo, Pfizer, Novartis, AstraZeneca and Bayer.Others are not far behind. MNCs have been smart in integrating emerging markets into their core operations. What needs furthet attention is a keener understanding on the part of MNCs re the operating environment in emrging markets and management cadre of more people with deep experience of operating in EMs.
Analysis
With flat sales of pharmaceuticals in developed markets of USA and Europe the emphasis on emerging markets makes a lot of sense.There is high level of underserved population in emerging markets and with growing incomes the desire to have good healthcare is high.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
